A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis

Gian Domenico Borasio; W. Robberecht; P. N. Leigh; J. Emile; R. J. Guiloff; F. Jerusalem; V. Silani; P. E. Vos; J. H J Wokke; T. Dobbins

A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis

Gian Domenico Borasio, W. Robberecht, P. N. Leigh, J. Emile, R. J. Guiloff, F. Jerusalem, V. Silani, P. E. Vos, J. H J Wokke, T. Dobbins

Fondazione Istituto Auxologico Italiano

Research output: Contribution to journal › Article › peer-review

Abstract

To test the safety and efficacy of recombinant human insulin-like growth factor-I (rhIGF-I) in ALS, 183 patients from eight European centers were randomized to receive double-blind placebo (n = 59) or rhIGF-I 0.1 mg/kg/day (n = 124) subcutaneously for 9 months. At study completion, the primary efficacy outcome measure (change in disease progression as assessed by the Appel ALS rating scale) showed no significant difference between treatment groups. RhIGF-I appeared to be safe and well-tolerated.

Original language	English
Pages (from-to)	583-586
Number of pages	4
Journal	Neurology
Volume	51
Issue number	2
Publication status	Published - Aug 1998

ASJC Scopus subject areas

Neuroscience(all)

Cite this

@article{9701045142cd4285aca82b37b3725f04,

title = "A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis",

abstract = "To test the safety and efficacy of recombinant human insulin-like growth factor-I (rhIGF-I) in ALS, 183 patients from eight European centers were randomized to receive double-blind placebo (n = 59) or rhIGF-I 0.1 mg/kg/day (n = 124) subcutaneously for 9 months. At study completion, the primary efficacy outcome measure (change in disease progression as assessed by the Appel ALS rating scale) showed no significant difference between treatment groups. RhIGF-I appeared to be safe and well-tolerated.",

author = "Borasio, {Gian Domenico} and W. Robberecht and Leigh, {P. N.} and J. Emile and Guiloff, {R. J.} and F. Jerusalem and V. Silani and Vos, {P. E.} and Wokke, {J. H J} and T. Dobbins",

year = "1998",

month = aug,

language = "English",

volume = "51",

pages = "583--586",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis

AU - Borasio, Gian Domenico

AU - Robberecht, W.

AU - Leigh, P. N.

AU - Emile, J.

AU - Guiloff, R. J.

AU - Jerusalem, F.

AU - Silani, V.

AU - Vos, P. E.

AU - Wokke, J. H J

AU - Dobbins, T.

PY - 1998/8

Y1 - 1998/8

N2 - To test the safety and efficacy of recombinant human insulin-like growth factor-I (rhIGF-I) in ALS, 183 patients from eight European centers were randomized to receive double-blind placebo (n = 59) or rhIGF-I 0.1 mg/kg/day (n = 124) subcutaneously for 9 months. At study completion, the primary efficacy outcome measure (change in disease progression as assessed by the Appel ALS rating scale) showed no significant difference between treatment groups. RhIGF-I appeared to be safe and well-tolerated.

AB - To test the safety and efficacy of recombinant human insulin-like growth factor-I (rhIGF-I) in ALS, 183 patients from eight European centers were randomized to receive double-blind placebo (n = 59) or rhIGF-I 0.1 mg/kg/day (n = 124) subcutaneously for 9 months. At study completion, the primary efficacy outcome measure (change in disease progression as assessed by the Appel ALS rating scale) showed no significant difference between treatment groups. RhIGF-I appeared to be safe and well-tolerated.

UR - http://www.scopus.com/inward/record.url?scp=0031722582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031722582&partnerID=8YFLogxK

M3 - Article

C2 - 9710040

AN - SCOPUS:0031722582

SN - 0028-3878

VL - 51

SP - 583

EP - 586

JO - Neurology

JF - Neurology

IS - 2

ER -

A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this